Loxo Oncology to Present at the Cowen and Company 38th Annual Health Care Conference
March 06 2018 - 6:45AM
Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company
innovating the development of highly selective medicines for
patients with genetically defined cancers, today announced that
Joshua H. Bilenker, M.D., chief executive officer, will present a
corporate overview at the Cowen and Company 38th Annual Health Care
Conference in Boston on Tuesday, March 13, 2018 at 10:00 a.m. ET.
A live broadcast of the presentation will be available at
http://ir.loxooncology.com/. An archived replay of the presentation
will be available on the company’s website for 30 days following
the presentation.
About Loxo OncologyLoxo Oncology is a
biopharmaceutical company innovating the development of highly
selective medicines for patients with genetically defined cancers.
Our pipeline focuses on cancers that are uniquely dependent on
single gene abnormalities, such that a single drug has the
potential to treat the cancer with dramatic effect. We believe that
the most selective, purpose-built medicines have the highest
probability of maximally inhibiting the intended target, thereby
delivering best-in-class disease control and safety. Our management
team seeks out experienced industry partners, world-class
scientific advisors and innovative clinical-regulatory approaches
to deliver new cancer therapies to patients as quickly and
efficiently as possible. For more information, please visit the
company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:Jacob S. Van NaardenChief Business
Officerjake@loxooncology.com
Investors:Peter RahmerThe Trout Group,
LLC646-378-2973prahmer@troutgroup.com
Media:Dan Budwick1AB Media973-271-6085dan@1abmedia.com
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Jun 2024 to Jul 2024
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Jul 2023 to Jul 2024